Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone

Journal of Steroid Biochemistry and Molecular Biology

Volumn 110, Issue 1-2, 2008, Pages 56-66

  Korhonen, Tuomas ^a,b,c   Turpeinen, Miia ^d,e   Tolonen, Ari ^d,e   Laine, Kari ^b,c   Pelkonen, Olavi ^d  

^a UNIVERSITY OF TURKU   (Finland)

^b TYKSLAB   (Finland)

^c Medbase Ltd   (Finland)

^d UNIVERSITY OF OULU   (Finland)

^e Novamass Analytical Ltd   (Finland)

Author keywords

Cytochrome P450; Lynestrenol; Metabolism; Norethindrone; Prodrug

Indexed keywords

AMFEBUTAMONE; AMODIAQUINE; CHLORZOXAZONE; COUMARIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DRUG METABOLITE; ETHOXYRESORUFIN; FLUCONAZOLE; FLUVOXAMINE; KETOCONAZOLE; LYNESTRENOL; MELATONIN; MIDAZOLAM; NORETHISTERONE; OMEPRAZOLE; PYRIDINE; QUERCETIN; QUINIDINE; RADAFAXINE; RECOMBINANT ENZYME; SULFAPHENAZOLE; TESTOSTERONE; TICLOPIDINE; TOLBUTAMIDE; TRANYLCYPROMINE;

ARTICLE; CATALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ANTAGONISM; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; DRUG TRANSFORMATION; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; INCUBATION TIME; LIVER MICROSOME; LIVER PARENCHYMA; PROTEIN EXPRESSION;

ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FLUCONAZOLE; HUMANS; HYDROXYLATION; KETOCONAZOLE; LYNESTRENOL; MICROSOMES, LIVER; NORETHINDRONE; SULFAPHENAZOLE;

EID: 44649188476     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.09.025     Document Type: Article

References (48)

1. Schindler A.E., Campagnoli C., Druckmann R., Huber J., Pasqualini J.R., Schweppe K.W., and Thijssen J.H. Classification and pharmacology of progestins. Maturitas 46 Suppl. 1 (2003) S7-S16
2. Mazaheri A., Fotherby K., and Chapman J.R. Metabolism of lynestrenol to norethisterone by liver homogenate. J. Endocrinol. 47 2 (1970) 251-252
3. 14C]lynestrenol in man. J. Endocrinol. 42 2 (1968) 337-343
4. Kuhl H., Bremser H.J., and Taubert H.D. Serum levels and pharmacokinetics of norethisterone after ingestion of lynestrenol: its relation to dose and stage of the menstrual cycle. Contraception 26 3 (1982) 303-315
5. Kontula K., Janne O., Vihko R., de Jager E., de Visser J., and Zeelen F. Progesterone-binding proteins: in vitro binding and biological activity of different steroidal ligands. Acta Endocrinol. (Copenh.) 78 3 (1975) 574-592
6. Hümpel M., Wendt H., Dogs G., Weiss C., Rietz S., and Speck U. Intraindividual comparison of pharmacokinetics parameters of d-norgestrel, lynestrenol, and cyproterone acetate in 6 women. Contraception 16 2 (1977) 199-215
7. Shrimanker K., Akpoviroro J., Fotherby K., and Watson J. Bioavailability of lynestrenol. Arzneimittelforschung 30 3 (1980) 500-502
8. Back D.J., Breckenridge A.M., Crawford F.E., Mciver M., Orme M.L., Park B.K., Rowe P.H., and Smith E. Kinetics of norethindrone in women. I. Radioimmunoassay and concentrations during multiple dosing. Clin. Pharmacol. Ther. 24 4 (1978) 439-447
9. Back D.J., Breckenridge A.M., Crawford F.E., Mciver M., Orme M.L., Rowe P.H., and Smith E. Kinetics of norethindrone in women. II. Single-dose kinetics. Clin. Pharmacol. Ther. 24 4 (1978) 448-453
10. Singh H., Uniyal J.P., Jha P., Murugesan K., Takkar D., Hingorani V., and Laumas K.R. Pharmacokinetics of norethindrone acetate in women. Am. J. Obstet. Gynecol. 135 3 (1979) 409-414
11. Zalanyi S., Landgren B.M., and Johannisson E. Pharmacokinetics, pharmacodynamic and endometrial effects of a single dose of 200 mg norethisterone enanthate. Contraception 30 3 (1984) 225-237
12. Back D.J., Breckenridge A.M., Crawford F., MacIver M., Orme M.L., Park B.K., Rowe P.H., and Smith E. The effect of rifampicin on norethisterone pharmacokinetics. Eur. J. Clin. Pharmacol. 15 3 (1979) 193-197
13. Barditch-Crovo P., Trapnell C.B., Ette E., Zacur H.A., Coresh J., Rocco L.E., Hendrix C.W., and Flexner C. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin. Pharmacol. Ther. 65 4 (1999) 428-438
14. Doose D.R., Wang S.S., Padmanabhan M., Schwabe S., Jacobs D., and Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 44 4 (2003) 540-549
15. Hall S.D., Wang Z., Huang S.M., Hamman M.A., Vasavada N., Adigun A.Q., Hilligoss J.K., Miller M., and Gorski J.C. The interaction between St. John's wort and an oral contraceptive. Clin. Pharmacol. Ther. 74 6 (2003) 525-535
16. van Giersbergen P.L., Halabi A., and Dingemanse J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int. J. Clin. Pharmacol. Ther. 44 3 (2006) 113-118
17. Pelkonen O., Kaltiala E.H., Larmi T.K., and Karki N.T. Cytochrome P-450-linked monooxygenase system and drug induced spectral interactions in human liver microsomes. Chem. Biol. Interact. 9 (1974) 205-216
18. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
19. http://www.fda.gov/cder/guidance/6695dft.html
20. Lewis D.F., and Dickins M. Substrate SARs in human P450s. Drug Discov. Today 7 17 (2002) 918-925
21. Turpeinen M., Uusitalo J., Jalonen J., and Pelkonen O. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur. J. Pharm. Sci. 24 1 (2005) 123-132
22. Äbelö A., Andersson T.B., Antonsson M., Naudot A.K., Skånberg I., and Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab. Dispos. 28 8 (2000) 966-972
23. Taavitsainen P., Juvonen R., and Pelkonen O. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab. Dispos. 29 3 (2001) 1-6
24. Turpeinen M., Nieminen R., Juntunen T., Taavitsainen P., Raunio H., and Pelkonen O. Selective inhibition of CYP2B6 catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab. Dispos. 32 6 (2004) 626-631
25. Turpeinen M., Korhonen L.E., Tolonen A., Uusitalo J., Juvonen R., Raunio H., and Pelkonen O. Cytochrome P450 (CYP) inhibition screening: comparison of three tests. Eur. J. Pharm. Sci. 29 2 (2006) 130-138
26. Diaz-Cruz M.S., Lopez de Alda M.J., Lopez R., and Barcelo D. Determination of estrogens and progestogens by mass spectrometric techniques (GC/MS, LC/MS and LC/MSMS). J. Mass Spectrom. 38 9 (2003) 917-923
27. Nielen M.W., Vissers J.P., Fuchs R.E., van Velde J.W., and Lommen A. Screening for anabolical streroids and related compounds in illegal cocktails by liquid chromatography/time-of-flight mass spectrometry and liquid chromatography/quadrupole time-of-flight tandem mass spectrometry with accurate mass measurement. Rapid Commun. Mass Spectrom. 15 17 (2001) 1577-1785
28. Williams T.M., Kind A.J., Houghton E., and Hill D.W. Electrospray collision induced dissociation of testosterone and testosterone hydroxy analogs. J. Mass Spectrom. 34 3 (1999) 206-216
29. Rostami-Hodjegan A., and Tucker G.T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6 2 (2007) 140-148
30. Back D.J., Tjia J.F., Karbwang J., and Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br. J. Clin. Pharmacol. 26 1 (1988) 23-29
31. Veronese M.E., Miners J.O., Randles D., Gregov D., and Birkett D.J. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin. Pharmacol. Ther. 47 3 (1990) 403-411
32. Wienkers L.C., Wurden C.J., Storch E., Kunze K.L., Rettie A.E., and Trager W.F. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab. Dispos. 24 5 (1996) 610-614
33. Niwa T., Inoue-Yamamoto S., Shiraga T., and Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol. Pharm. Bull. 28 9 (2005) 1813-1816
34. Kunze K.L., Wienkers L.C., Thummel K.E., Trager W.F., and Warfarin-fluconazole I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab. Dispos. 24 4 (1996) 414-421
35. Venkatakrishnan K., von Moltke L.L., and Greenblatt D.J. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet. 38 2 (2000) 111-180
36. Pelkonen O., Maenpaa J., Taavitsainen P., Rautio A., and Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28 12 (1998) 1203-1253
37. Laine K., Yasar U., Widen J., and Tybring G. A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes. Pharmacol. Toxicol. 93 2 (2003) 77-81
38. de Morais S.M., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., and Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46 4 (1994) 594-598
39. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., Zhang Z.Y., Kaminsky L.S., Shenfield G.M., Miners J.O., Birkett D.J., and Goldstein J.A. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6 4 (1996) 341-349
40. Nakamura K., Goto F., Ray W.A., McAllister C.B., Jacqz E., Wilkinson G.R., and Branch R.A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 38 4 (1985) 402-408
41. Alvan G., Bechtel P., Iselius L., and Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 39 6 (1990) 533-537
42. Bertilsson L., Lou Y.Q., Du Y.L., Liu Y., Kuang T.Y., Liao X.M., Wang K.Y., Reviriego J., Iselius L., and Sjoqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 51 4 (1992) 388-397
43. Yasar U., Eliasson E., Dahl M.L., Johansson I., Ingelman-Sundberg M., and Sjoqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem. Biophys. Res. Commun. 254 3 (1999) 628-631
44. Aithal G.P., Day C.P., Kesteven P.J., and Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 9154 (1999) 717-719
45. Yasar U., Tybring G., Hidestrand M., Oscarson M., Ingelman-Sundberg M., Dahl M.L., and Eliasson E. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab. Dispos. 29 7 (2001) 1051-1056
46. Ding X., and Kaminsky L.S. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 149-173
47. Pelkonen O., Turpeinen M., Uusitalo J., Rautio A., and Raunio H. Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin. Pharmacol. Toxicol. 96 3 (2006) 167-175
48. Stanczyk F.Z., and Roy S. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception 42 1 (1990) 67-96